Back to results
US 2009/0214525 A1Published application
Novel anti-igf-ir antibodies and uses thereof
AssigneePierre Fabre Medicament
InventorsLiliane Goetsch, Nathalie Corvaia
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneePierre Fabre Medicament
InventorsLiliane Goetsch, Nathalie Corvaia
Estimating the term…
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
An isolated antibody, or one of its functional fragments, said antibody or one of its said fragments being capable of binding to the human insulin-like growth factor I receptor IGF-IR and, if necessary, inhibiting the natural attachment of its ligands IGF1 and/or IGF2 and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-R, characterized in that it comprises a light chain comprising at least one complementarity determining region CDR chosen from the CDRs of sequence SEQ ID No. 1, 2 or 3, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID No. 1, 2 or 3, or in that it comprises a heavy chain comprising at least one CDR chosen from the CDRs of sequence SEQ ID Nos. 4, 5 and 6, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID Nos. 4, 5 and 6.
An isolated antibody, or one of its functional fragments, said antibody or one of its said fragments being capable of binding to the human insulin-like growth factor I receptor IGF-IR and, if necessary, inhibiting the natural attachment of its ligands IGF1 and/or IGF2 and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, characterized in that it comprises a light chain comprising at least one complementarity determining region CDR chosen from the CDRs of sequence SEQ ID No. 7, 8 or 9, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID No. 7, 8 or 9, or in that it comprises a heavy chain comprising at least one CDR chosen from the CDRs of sequence SEQ ID Nos. 10, 11 and 12, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID Nos. 10, 11 and 12.
An isolated antibody, or one of its functional fragments, said antibody or one of its said fragments being capable of binding to the human insulin-like growth factor I receptor IGF-IR and, if necessary, inhibiting the natural attachment of its ligands IGF1 and/or IGF2 and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, characterized in that it comprises a light chain comprising at least one complementarity determining region CDR chosen from the CDRs of sequence SEQ ID No. 13, 14 or 15, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID No. 13, 14 or 15, or in that it comprises a heavy chain comprising at least one CDR chosen from the CDRs of sequence SEQ ID Nos. 16, 17 and 18, or at least one CDR whose sequence has at least 80% identity after optimum alignment with the sequence SEQ ID Nos. 16, 17 and 18.
A murine hybridoma deposited at the CNCM, Institut Pasteur, Paris, on Jul. 1st, 2004 under the number I-3249.
The use as claimed in one of claims of 20 to 22 for the preparation of a medicament intended for the prevention or for the treatment of cancer.
The use as claimed in one of claims of 20 to 22 for the preparation of a medicament intended for the prevention or for the treatment of psoriasis or atherosclerosis.
Dependencies are inferred from the claim text.